window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

Ethris

  • CDMOs & Manufacturing,Drug Delivery & Formulation,Partnerships & Funding,Pharmaceuticals and therapeutics,RNA Therapeutics,Technology and platforms

    Evonik and Ethris partner on lipid nanoparticle delivery platform

    Evonik and Ethris have agreed a partnership to develop and [...]

    September 18, 2025
  • Cell & Gene Therapy,Drug Development,Patient Centricity,Research & Development,RNA Therapeutics

    Ethris begins Phase 2a trial of intranasal mRNA candidate ETH47 for virus-triggered asthma

    Ethris has dosed the first patient in a Phase 2a [...]

    August 5, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding

    Ethris signs strategic collaboration with Thermo Fisher Scientific to provide access to mRNA technology platforms

    Partnership further validates Ethris’ novel technology platform based on stabilized [...]

    June 16, 2025
  • Biologics & Biosimilars,Cell & Gene Therapy,Drug Development

    Ethris secures €10 million EU4Health grant for ETH47 antiviral development

    Ethris GmbH has been awarded a €10 million grant from [...]

    May 6, 2025
  • Drug Delivery & Formulation

    Ethris and Lonza collaborate to develop spray-dried mRNA vaccines for respiratory disease prevention

    April 15, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top